Epigenetic alteration by DNA promoter hypermethylation of genes related to transforming growth factor-β (TGF-β) signaling in cancer

Cancers

Volumn 3, Issue 1, 2011, Pages 982-993

  Khin, Sann Sanda ^a,b   Kitazawa, Riko ^a,c   Kondo, Takeshi ^a   Idei, Yuka ^a   Fujimoto, Masayo ^a   Haraguchi, Ryuma ^c   Mori, Kiyoshi ^a   Kitazawa, Sohei ^a,c  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Department of Medical Research ^*  (Myanmar)

^c EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer; Methylation; TGF signaling

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AFLATOXIN B1; BONE MORPHOGENETIC PROTEIN; CIGARETTE SMOKE; INHIBITORY SMAD PROTEIN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; RECEPTOR REGULATED SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD5 PROTEIN; SMAD6 PROTEIN; SMAD7 PROTEIN; SMAD8 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ACUTE GRANULOCYTIC LEUKEMIA; BAMBI GENE; BLADDER CANCER; BMP2 GENE; BMP3B GENE; BMP6 GENE; BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CPG ISLAND; CPG ISLAND METHYLATOR PHENOTYPE; DESMOID TUMOR; DNA METHYLATION; DRUG TARGETING; EBF3 GENE; ENVIRONMENTAL FACTOR; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; FBXO32 GENE; FUSSEL18 GENE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE SILENCING; HEAD AND NECK CARCINOMA; HUMAN; IRX1 GENE; LIVER CELL CARCINOMA; LYMPHOMA; MALIGNANT MESOTHELIOMA; MALIGNANT NEOPLASTIC DISEASE; ONCOGENE; ONCOGENE C MYC; OVARY CANCER; PHENOTYPE; PROMOTER REGION; PROSTATE CANCER; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REVIEW; SEPT9 GENE; SIGNAL TRANSDUCTION; SLC5A8 GENE; SMAD4 GENE; SOLID TUMOR; STOMACH CANCER; T CELL LEUKEMIA; TRISTETRAPOLIN GENE; TUMOR MICROENVIRONMENT; ULTRAVIOLET RADIATION; UTERINE CERVIX CANCER;

EID: 79953725147     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3010982     Document Type: Review

References (78)

1. Jaenisch, R.; Bird, A. Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals. Nat. Genet. 2003, 33, 245-254.
2. Herceg, Z. Epigenetics and cancer: Towards an evaluation of the impact of environmental and dietary factors. Mutagenesis 2007, 22, 91-103.
3. Nan, X.; Ng, H.H.; Johnson, C.A.; Laherty, C.D.; Turner, B.M.; Eisenman, R.N.; Bird, A. Transcriptional repression by the methyl-CpG-binding protein M eCP2 involves a histone deacetylase complex. Nature 1998, 393, 386-389.
4. Bird, A.P.; Wolffe, A.P. Methylation-induced repression-belts, braces, and chromatin. Cell 1999, 99, 451-454.
5. Issa, J.P. CpG island methylator phenotype in cancer. Nat. Rev. Cancer 2004, 4, 988-993.
6. Chen, Y.G.; Lui, H.M.; Lin, S.L.; Lee, J.M.; Ying, S.Y. Regulation of cell proliferation: Apoptosis and carcinogenesis by activin. Exp. Biol. Med. 2002, 227, 75-87.
7. Khin, S.S.; Kitazawa, R.; Win, N.; Aye, T.T.; Mori, K.; Kondo, T.; Kitazawa, S. BAMBI gene is epigenetically silenced in subset of high-grade bladder cancer. Int. J. Cancer 2009, 125, 328-338.
8. Leivonen, S.K.; Kahari, V.M. Transforming growth factor-β signaling in cancer invasion and metastasis. Int. J. Cancer 2007, 121, 2119-2124.
9. Akhurst, R.J.; Balmain, A. Genetic events and the role of TGF beta in epithelial tumour progression. J. Pathol. 1999, 187, 82-90.
10. McRonald, F.E.; Morris, M.R.; Gentle, D.; Winchester, L.; Baban, D.; Ragoussis, J.; Clarke, N.W.; Brown, M.D.; Kishida, T.; Yao, M.; Latif, F.; Maher, E.R. CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma. Mol. Cancer 2009, 8, 31.
11. Ting, A.H.; McGarvey, K.M.; Baylin, S.B. The cancer epigenome-components and functional correlates. Genes Dev. 2006, 20, 3215-3231.
12. Kane, M.F.; Loda, M.; Gaida, G.M.; Lipman, J.; Mishra, R.; Goldman, H.; Jessup, J.M.; Kolodner, R. Methylation of the hM LH1 promoter correlates with lack of expression of hM LH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997, 57, 808-811.
13. Issa, J.P. CpG island methylator phenotype in cancer. Nat. Rev. Cancer 2004, 4, 988-993.
14. Whitehall, V.L.; Wynter, C.V.A.; Walsh, M.D.; Simms, L.A.; Purdie, D.; Pandeya, N.; Young, J.; Meltzer, S.J.; Leggett, B.A.; Jass, J.R. Morphological and molecular heterogeneity within nonmicrosatellite instability-high colorectal cancer. Cancer Res. 2002, 62, 6011-6014.
15. van Rijnsoever, M.; Grieu, F.; Elsaleh, H.; Joseph, D.; Iacopetta, B. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 2002, 51, 797-802.
16. Dulaimi, E.; Ibanez de Caceres, I.; Uzzo, R.G.; Al-Saleem, T.; Greenberg, R.E.; Polascik, T.J.; Babb, J.S.; Grizzle, W.E.; Cairns, P. Promoter hypermethylation profile of kidney cancer. Clin. Cancer Res. 2004, 10, 3972-3979.
17. Li, Q.; Jedlicka, A.; Ahuja, N.; Gibbons, M.C.; Baylin, S.B.; Burger, P.C.; Issa, J.P. Concordant methylation of the ER and N33 genes in glioblastoma multiforme. Oncogene 1998, 16, 3197-3202.
18. Toyota, M.; Ahuja, N.; Suzuki, H.; Itoh, F.; Ohe-Toyota, M.; Imai, K.; Baylin, S.B.; Issa, J.P.J. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res. 1999, 59, 5438-5442.
19. Kim, H.; Kim, Y.H.; Kim, S.E.; Kim, N.G.; Noh, S.H.; Kim, H. Concerted promoter hypermethylation of hMLH1, p16INK4A, and E-cadherin in gastric carcinomas with microsatellite instability. J. Pathol. 2003, 200, 23-31.
20. Shen, L.; Ahuja, N.; Shen, Y.; Habib, N.A.; Toyota, M.; Rashid, A.; Issa, J.P.J. DNA methylation and environmental exposures in human hepatocellular carcinoma. J. Natl. Cancer Inst. 2002, 94, 755-761.
21. Ueki, T.; Toyota, M.; Sohn, T.; Yeo, C.J.; Issa, J.P.; Hruban, R.H.; Goggins, M. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res. 2000, 60, 1835-1839.
22. Issa, J.P. M ethylation and prognosis: Of molecular clocks and hypermethylator phenotypes. Clin. Cancer Res. 2003, 9, 2879-2881.
23. Strathdee, G.; Appleton, K.; Illand, M.; Millan, D.W. M.; Sargent, J.; Paul, J.; Brown, R. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am. J. Pathol. 2001, 158, 1121-1127.
24. Hoque, M.O.; Rosenbaum, E.; Westra, W.H.; Xing, M.; Ladenson, P.; Zeiger, M.A.; Sidransky, D.; Umbricht, C.B. Quantitative assessment of promoter methylation profiles in thyroid neoplasms. J. Clin. Endocrinol. Metab. 2005, 90, 4011-4018.
25. Garcia-Manero, G.; Daniel, J.; Smith, T.L.; Kornblau, S.M.; Lee, M.S.; Kantarjian, H.M.; Issa, J.P.J. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin. Cancer Res. 2002, 8, 2217-2224.
26. Toyota, M.; Kopecky, K.J.; Toyota, M.O.; Jair, K.W.; Willman, C.L.; Issa, J.P.J. Methylation profiling in acute myeloid leukemia. Blood 2001, 97, 2823-2829.
27. Egger, G.; Liang, G.; Aparicio, A.; Jones, P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429, 457-463.
28. Fraga, M.F.; Ballestar, E.; Villar-Garea, A.; Boix-Chornet, M.; Espada, J.; Schotta, G.; Bonaldi, T.; Haydon, C.; Ropero, S.; Petrie, K.; et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 2005, 37, 391-400.
29. Seligson, D.B.; Horvath, S.; Shi, T.; Yu, H.; Tze, S.; Grunstein, M.; Kurdistani, S.K. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435, 1262-1266.
30. Shames, D.S.; Minna, J.D.; Gazdar, A.F. DNA Methylation in Health, Disease, and Cancer. Curr. Mol. Med. 2007, 7, 85-102.
31. Bierie, B.; Moses, H.L. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 2006, 6, 506-520.
32. Li, A.G.; Lu, S.L.; Han, G.; Hoot, K.E.; Wang, X.J. Role of TGFbeta in skin inflammation and carcinogenesis. Mol. Carcinog. 2006, 45, 389-396.
33. Feng, X.H.; Derynck, R. Specificity and versatility in TGF-beta signaling through SM ADS. Annu. Rev. Cell Dev. Biol. 2005, 21, 659-693.
34. ten Dijke, P.; Hill, C.S. New insights into TGF-beta-Smad signalling. Trends Biochem. Sci. 2004, 29, 265-273.
35. Derynck, R.; Zhang, Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425, 577-584.
36. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57-70.
37. Leivonen, S.K.; Ala-aho, R.; Koli, K.; Grenman, R.; Peltonen, J.; Kahari, V.M. Activation of Smad signaling enhances collagenase-3 (MMP-13) expression and invasion of head and neck squamous carcinoma cells. Oncogene 2006, 25, 2588-2600.
38. Pardali, K.; Moustakas, A. Actions of TGF-b as tumor suppressor and pro-metastatic factor in human cancer Biochim. Biophys. Acta 2007, 1775, 21-62.
39. Derynck, R.; Akhurst, R.J.; Balmain, A. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 2001, 29, 117-129.
40. Cohen, M.M., Jr. TGF-β/Smad signaling system and its pathologic correlates. Am. J. Med. Genet. A 2003, 116, 1-10.
41. Issa, J.P.; Ahuja, N.; Toyota, M.; Bronner, M.P.; Brentnall, T.A. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 2001, 61, 3573-3577.
42. Eads, C.A.; Lord, R.V.; Kurumboor, S.K.; Wickramasinghe, K.; Skinner, M.L.; Long, T.I.; Peters, J.H.; DeMeester, T.R.; Danenberg, K.D.; Danenberg, P.V.; et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarci nom a. Cancer Res. 2000, 60, 5021-5026.
43. Zochbauer-Muller, S.; Fong, K.M.; Virmani, A.K.; Geradts, J.; Gazdar, A.F.; Minna, J.D. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001, 61, 249-255.
44. Chen, W.; Gao, N.; Shen, Y.; Cen, J.N. Hypermethylation downregulates Runx3 gene expression and its restoration suppresses gastric epithelial cell growth by inducing p27 and caspase3 in human gastric cancer. J. Gastroenterol. Hepatol. 2010, 25, 823-831.
45. Dachrut, S.; Banthaisong, S.; Sripa, M.; Paeyao, A.; Ho, C.; Lee, S.A.; Kosinski, C.; Patil, M.A.; Zhang, J.; Chen, X.; et al. DNA copy-number loss on 1p36.1 harboring RUNX3 with promoter hypermethylation and associated loss of RUNX3 expression in liver fluke-associated intrahepatic cholangiocarcinoma. Asian Pac. J. Cancer Prev. 2009, 10, 575-582.
46. Gao, F.; Huang, C.; Lin, M.; Wang, Z.; Shen, J.; Zhang, H.; Jiang, L.; Chen, Q. Frequent inactivation of RUNX3 by promoter hypermethylation and protein mislocalization in oral squamous cell carcinomas. J. Cancer Res. Clin. Oncol. 2009, 135, 739-747.
47. Nomoto, S.; Kinoshita, T.; Mori, T.; Kato, K.; Sugimoto, H.; Kanazumi, N.; Takeda, S.; Nakao, A. Adverse prognosis of epigenetic inactivation in RUNX3 gene at 1p36 in human pancreatic cancer. Br. J. Cancer 2008, 98, 1690-1695.
48. Long, C.; Yin, B.; Lu, Q.; Zhou, X.; Hu, J.; Yang, Y.; Yu, F.; Yuan, Y. Promoter hypermethylation of the RUNX3 gene in esophageal squamous cell carcinoma. Cancer Invest. 2007, 25, 685-690.
49. Park, W.S.; Cho, Y.G.; Kim, C.J.; Song, J.H.; Lee, Y.S.; Kim, S.Y.; Nam, S.W.; Lee, S.H.; Yoo, N.J.; Lee, J.Y. Hypermethylation of the RUNX3 gene in hepatocellular carcinoma. Exp. Mol. Med. 2005, 37, 276-281.
50. Cooper, S.J.; Zou, H.; Legrand, S.N.; Marlow, L.A.; von Roemeling, C.A.; Radisky, D.C.; Wu, K.J.; Hempel, N.; Margulis, V.; Tun, H.W.; et al. Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma. Oncogene 2010, 29, 2905-2915.
51. Muñoz-Antonia, T.; Torrellas-Ruiz, M.; Clavell, J.; Mathews, L.A.; Muro-Cacho, C.A.; Báez, A. Aberrant methylation inactivates transforming growth factor Beta receptor I in head and neck squamous cell carcinoma. Int. J. Otolaryngol. 2009, 2009, 848695.
52. de Carvalho, F.; Colleoni, G.W.; Almeida, M.S.; Carvalho, A.L.; Vettore, A.L. TGFbetaR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma. Int. J. Cancer 2009, 125, 1985-1991.
53. Shah, J.N.; Shao, G.; Hei, T.K.; Zhao, Y. Methylation screening of the TGFBI promoter in human lung and prostate cancer by methylation-specific PCR. BMC Cancer 2008, 8, 284.
54. Dumont, N.; Wilson, M.B.; Crawford, Y.G.; Reynolds, P.A.; Sigaroudinia, M.; Tlsty, T.D. Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc. Natl. Acad. Sci. USA 2008 105, 14867-14872.
55. Chou, J.L.; Su, H.Y.; Chen, L.Y.; Liao, Y.P.; Hartman-Frey, C.; Lai, Y.H.; Yang, H.W.; Deatherage, D.E.; Kuo, C.T.; Huang, Y.W.; et al. Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab Invest. 2010, 90, 414-425.
56. Sohn, B.H.; Park, I.Y.; Lee, J.J.; Yang, S.J.; Jang, Y.J.; Park, K.C.; Kim, D.J.; Lee, D.C.; Sohn, H.A.; Kim, T.W.; et al. Functional switching of TGF-beta1 signaling in liver cancer via epigenetic modulation of a single CpG site in TTP promoter. Gastroenterology 2010, 138, 1898-1908.
57. Bennett, K.L.; Romigh, T.; Eng, C. Disruption of transforming growth factor-beta signaling by five frequently methylated genes leads to head and neck squamous cell carcinoma pathogenesis. Cancer Res. 2009 69, 9301-9305.
58. Hypes, M.K.; Pirisi, L.; Creek, K.E. Mechanisms of decreased expression of transforming growth factor-beta receptor type I at late stages of HPV 16-mediated transformation. Cancer Lett. 2009, 282, 177-186.
59. Kitazawa, S.; Kitazawa, R.; Obayashi, C.; Yamamoto, T. Desmoid tumor with ossification in chest wall: possible involvement of BAMBI promoter hypermethylation in metaplastic bone formation. J. Bone Miner. Res. 2005, 20, 1472-1477.
60. Aitchison, A.A.; Veerakumarasivam, A.; Vias, M.; Kumar, R.; Hamdy, F.C.; Neal, D.E.; Mills, I.G. Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. Prostate 2008, 68, 661-674.
61. Kimura, K.; Toyooka, S.; Tsukuda, K.; Yamamoto, H.; Suehisa, H.; Soh, J.; Otani, H.; Kubo, T.; Aoe, K.; Fujimoto, N.; et al. The aberrant promoter methylation of BM P3b and BM P6 in malignant pleural mesotheliomas. Oncol. Rep. 2008, 20, 1265-1268.
62. Taniguchi, A.; Nemoto, Y.; Yokoyama, A.; Kotani, N.; Imai, S.; Shuin, T.; Daibata, M. Promoter methylation of the bone morphogenetic protein-6 gene in association with adult T-cell leukemia. Int. J. Cancer 2008, 123, 1824-1831.
63. Daibata, M.; Nemoto, Y.; Bandobashi, K.; Kotani, N.; Kuroda, M.; Tsuchiya, M.; Okuda, H.; Takakuwa, T.; Imai, S.; Shuin, T.; et al. Promoter hypermethylation of the bone morphogenetic protein-6 gene in malignant lymphoma. Clin. Cancer Res. 2007, 13, 3528-3535.
64. Wen, X.Z.; Akiyama, Y.; Baylin, S.B.; Yuasa, Y. Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas. Oncogene 2006, 25, 2666-2673.
65. Peto, J. Cancer epidemiology in the last century and the next decade. Nature 2001, 411, 390-395.
66. Mathers, J.C. The biological revolution-Towards a mechanistic understanding of the impact of diet on cancer risk. Mutat. Res. 2004, 551, 43-49.
67. Shen, L.; Ahuja, N.; Shen, Y.; Habib, N.A.; Toyota, M.; Rashid, A.; Issa, J.P.J. DNA methylation and environmental exposures in human hepatocellular carcinoma. J. Natl. Cancer Inst. 2002, 94, 755-761.
68. Kang, G.H.; Lee, S.; Kim, W.H.; Lee, H.W.; Kim, J.C.; Rhyu, M.G.; Ro, J.Y. Epstein-barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylatorphenotype-positive gastric carcinoma. Am. J. Pathol. 2002, 160, 787-794.
69. Waterland, R.A.; Jirtle, R.L. Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol. Cell Biol. 2003, 23, 5293-5300.
70. Herman, J.G.; Umar, A.; Polyak, K.; Ahuja, N.; Issa, J.P.; Markowitz, S.; Willson, J.K.; Hamilton, S.R.; Kinzler, K.W.; et al. Incidence and functional consequences of hM LH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA 1998, 95, 6870-6875.
71. Esteller, M.; Sparks, A.; Toyota, M.; Sanchez-Cespedes, M.; Capella, G.; Peinado, M.A.; Gonzalez, S.; Tarafa, G.; Sidransky, D.; Meltzer, S.J. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res. 2000, 60, 4366-4371.
72. Esteller, M.; Risques, R.A.; Toyota, M.; Capella, G.; Moreno, V.; Peinado, M.A.; Baylin, S.B.; Herman, J.G. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransf erase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res. 2001, 61, 4689-4692.
73. Chen, J.X.; Zheng, Y.; West, M.; Tang, M.S. Carcinogens preferentially bind at methylated CpG in the p53 mutational hot spots. Cancer Res. 1998, 58, 2070-2075.
74. Denissenko, M.F.; Pao, A.; Tang, M.; Pfeifer, G.P. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 1996, 274, 430-432.
75. Yoon, J.H.; Smith, L.E.; Feng, Z.; Tang, M.; Lee, C.S.; Pfeifer, G.P. Methylated CpG dinucleotides are the preferential targets for G-to-T transversion mutations induced by benzo[a]pyrene diol epoxide in mammalian cells: similarities with the p53 mutation spectrum in smokingassociated lung cancers. Cancer Res. 2001, 61, 7110-7117.
76. Laird, P.W.; Jackson-Grusby, L.; Fazeli, A.; Dickinson, S.L.; Jung, W.E.; Li, E.; Weinberg, R.A.; Jaenisch, R. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 1995, 81, 197-205.
77. Jones, P.A.; Baylin, S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3, 415-428.
78. Issa, J.P.J. DNA methylation as a therapeutic target in cancer. Clin. Cancer Res. 2007, 13, 1634-1637.